DE69622006T2 - Herstellung von Microspheren - Google Patents

Herstellung von Microspheren

Info

Publication number
DE69622006T2
DE69622006T2 DE69622006T DE69622006T DE69622006T2 DE 69622006 T2 DE69622006 T2 DE 69622006T2 DE 69622006 T DE69622006 T DE 69622006T DE 69622006 T DE69622006 T DE 69622006T DE 69622006 T2 DE69622006 T2 DE 69622006T2
Authority
DE
Germany
Prior art keywords
emulsion
microspheres
gas
aqueous phase
phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69622006T
Other languages
English (en)
Other versions
DE69622006D1 (de
Inventor
Nobuyuki Takechi
Seiji Ohtani
Akihiro Nagai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of DE69622006D1 publication Critical patent/DE69622006D1/de
Publication of DE69622006T2 publication Critical patent/DE69622006T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69622006T 1995-12-15 1996-12-13 Herstellung von Microspheren Expired - Lifetime DE69622006T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP32769095 1995-12-15

Publications (2)

Publication Number Publication Date
DE69622006D1 DE69622006D1 (de) 2002-08-01
DE69622006T2 true DE69622006T2 (de) 2002-10-24

Family

ID=18201894

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69635249T Expired - Lifetime DE69635249T2 (de) 1995-12-15 1996-12-13 Herstellung von Mikrosphären
DE69622006T Expired - Lifetime DE69622006T2 (de) 1995-12-15 1996-12-13 Herstellung von Microspheren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69635249T Expired - Lifetime DE69635249T2 (de) 1995-12-15 1996-12-13 Herstellung von Mikrosphären

Country Status (9)

Country Link
US (2) US5851451A (de)
EP (2) EP1142567B1 (de)
JP (1) JP4988660B2 (de)
AT (2) ATE305772T1 (de)
CA (1) CA2192782C (de)
DE (2) DE69635249T2 (de)
DK (1) DK1142567T3 (de)
ES (1) ES2249362T3 (de)
PT (1) PT1142567E (de)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
ATE288270T1 (de) * 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv Mikroverkapselte 1,2-benzazole
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
ATE192334T1 (de) 1995-11-09 2000-05-15 Microbiological Res Authority Mikroverkapselte dna zur impfung und gentherapie
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
CA2192782C (en) * 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
KR0162872B1 (ko) * 1996-04-01 1998-12-01 김은영 용매추출법을 이용한 생분해성 고분자 미립구의 개선된 제조방법 및 이를 이용한 국소염증 질환 치료용 미립구의 제조방법
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6291013B1 (en) * 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
ES2326209T3 (es) 2000-10-27 2009-10-05 Baxter Healthcare S.A. Produccion de microesferas.
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
EP2062593A3 (de) * 2000-12-01 2011-08-17 Takeda Pharmaceutical Company Limited Verfahren zur Herstellung einer Zubereitung mit bioaktiven Peptiden
WO2002049620A2 (en) 2000-12-21 2002-06-27 Inhale Therapeutic Systems, Inc. Induced phase transition method for the production of microparticles containing hydrophobic active agents
EP1408876A4 (de) 2001-06-22 2004-09-22 Durect Corp Koaxiale implantate nullter ordnung mit verlängerter freisetzung
TWI225416B (en) * 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
EP1418890B1 (de) * 2001-08-16 2008-05-14 Baxter International Inc. Darreichungsformen welche mikropartikel und treibgas enthalten
WO2003055470A1 (fr) * 2001-12-26 2003-07-10 Takeda Chemical Industries, Ltd. Nouvelle microsphere et son procede de production
CA2490351C (en) * 2002-06-25 2011-11-01 Takeda Pharmaceutical Company Limited Process for producing sustained-release composition
US20040121009A1 (en) * 2002-10-17 2004-06-24 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
US7164005B2 (en) 2002-10-17 2007-01-16 Alkermes, Inc. Microencapsulation and sustained release of biologically active polypeptides
SE0301431D0 (sv) 2003-05-19 2003-05-19 Dermagen Novel antimicrobial peptides
KR101137785B1 (ko) * 2003-07-18 2012-04-25 백스터 인터내셔널 인코포레이티드 제어된 상 분리에 의해 제조된 작은 구형 입자의 제조방법, 이용 방법 및 조성물
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
US20070092452A1 (en) * 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
AU2004258971A1 (en) * 2003-07-22 2005-02-03 Baxter Healthcare S.A. Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
RS51934B (en) * 2003-08-08 2012-02-29 Biovail Laboratories International Srl. BUPROPION HYDROCHLORIDE TABLE WITH MODIFIED RELEASE
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
CA2566199C (en) 2004-05-12 2013-10-22 Baxter International Inc. Delivery of as-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes
MXPA06012992A (es) 2004-05-12 2007-02-12 Baxter Int Microesferas que comprenden proteina y que muestran inyectabilidad en altas concentraciones de este agente.
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
PT1765294E (pt) 2004-05-12 2008-12-30 Baxter Healthcare Sa Microesferas de ácido nucleico, sua produção e entrega
EP1768668A2 (de) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multi-ppi-dosierform
TW200613012A (en) † 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
US20070254314A1 (en) * 2004-09-16 2007-11-01 Geier Mark R Methods of treating autism and autism spectrum disorders
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
CN101188996B (zh) * 2005-04-27 2013-03-27 巴克斯特国际公司 表面改性的微粒及其形成和使用方法
US7942867B2 (en) * 2005-11-09 2011-05-17 The Invention Science Fund I, Llc Remotely controlled substance delivery device
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8546451B2 (en) * 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US20070154546A1 (en) * 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
WO2007091958A1 (en) * 2006-02-10 2007-08-16 Dermagen Ab Novel antimicrobial peptides and use thereof
WO2007133153A1 (en) 2006-05-16 2007-11-22 Dermagen Ab Improved antimicrobial peptides
US20070281031A1 (en) * 2006-06-01 2007-12-06 Guohan Yang Microparticles and methods for production thereof
MX2009001226A (es) 2006-08-04 2009-03-20 Baxter Int Composicion basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nuevo inicio.
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
AU2007319577A1 (en) * 2006-10-06 2008-05-22 Baxter Healthcare S.A. Microencapsules containing surface-modified microparticles and methods of forming and using the same
NZ577281A (en) * 2006-12-18 2011-12-22 Takeda Pharmaceutical Sustained-release composition and method for producing the same
US20080227805A1 (en) 2007-02-28 2008-09-18 Abbott Laboratories Sustained release parenteral formulations of buprenorphine
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
ITSA20070024A1 (it) * 2007-07-27 2009-01-28 Univ Degli Studi Salerno Processo continuo per la produzione di microsfere mediante liquidi espansi.
CN102014638A (zh) * 2007-10-12 2011-04-13 武田制药北美公司 与食物摄入无关的治疗胃肠病症的方法
EP2240155B1 (de) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
US8133861B2 (en) * 2008-02-29 2012-03-13 Alseres Pharmaceuticals, Inc. Systemic purine administration: modulating axonal outgrowth of central nervous system neurons
CA2730760A1 (en) * 2008-07-16 2010-01-21 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles containing bioactive peptides
US8367427B2 (en) 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8323685B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US20100047292A1 (en) * 2008-08-20 2010-02-25 Baxter International Inc. Methods of processing microparticles and compositions produced thereby
BRPI0918904B8 (pt) 2008-09-04 2021-05-25 Amylin Pharmaceuticals Inc formulação pré-misturada fabricada para injeção, seu uso e kit compreendendo a mesma
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
GB0916578D0 (en) 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
GB0916576D0 (en) 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
EP2598553B1 (de) * 2010-07-26 2016-04-27 Université de Genève Zusammensetzungen mit polymeren aus 2-hydroxyalkyl-säuren
GB201016433D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Apparatus and method for making solid beads
GB201016436D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Method of making solid beads
CN107929730A (zh) 2011-01-19 2018-04-20 坎塔吉亚有限责任公司 抗il1rap抗体及其治疗人类的用途
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
GB2493540A (en) 2011-08-10 2013-02-13 Follicum Ab Agents for stimulating hair growth in mammals
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
DK2771320T3 (en) 2011-10-24 2016-10-03 Endo Pharmaceuticals Inc Cyclohexylamines
WO2013061083A2 (en) 2011-10-28 2013-05-02 Fredax Ab Therapeutic agents and uses thereof
GB201214169D0 (en) 2012-08-08 2012-09-19 Biostatus Ltd New compounds and uses thereof
PT3071595T (pt) 2013-11-19 2019-06-11 Fredax Ab Anticorpo anti calicreína-2 humanizado
CA2933811C (en) 2013-12-16 2021-02-09 Asana Biosciences, Llc P2x3 and/or p2x2/3 compounds and methods
GB201405784D0 (en) 2014-03-31 2014-05-14 Enzymatica Ab Novel methods, polypeptides and uses thereof
EP3099317B1 (de) 2014-01-29 2021-08-04 Enzymatica AB Kabeljau trypsin zur behandlung von mikrobiellen infektionen bei immunodefizienz
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
EP3131532A1 (de) 2014-04-16 2017-02-22 Veyx-Pharma GmbH Veterinärpharmazeutische zusammensetzung und deren verwendung
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CA2983403A1 (en) 2015-04-21 2016-10-27 Gtx, Inc. Selective androgen receptor degrader (sard) ligands and methods of use thereof
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
EP3285757B1 (de) 2015-04-21 2021-09-22 Oncternal Therapeutics, Inc. Selektive liganden des androgenrezeptordegraders (sard) und verfahren zur verwendung davon
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10017471B2 (en) 2015-04-21 2018-07-10 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
US10035763B2 (en) 2015-04-21 2018-07-31 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US9834507B2 (en) 2015-04-21 2017-12-05 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
EP3302354B1 (de) 2015-06-03 2023-10-04 i2o Therapeutics, Inc. Systeme zum einsetzen eines implantats
EP3120866A1 (de) 2015-07-24 2017-01-25 Zymetech ehf. Verwendung von marineserinproteasen zur entfernung, vorbeugung und hemmung der bildung und des wachstums von biofilmen
EP3359189B1 (de) 2015-10-05 2021-06-23 Fredax AB Humanisierte anti-psa (5a10) antikörper
CN105287390A (zh) * 2015-11-20 2016-02-03 北京博恩特药业有限公司 一种长效醋酸亮丙瑞林微球及其制备方法
GB201601136D0 (en) 2016-01-21 2016-03-09 Mörgelin Matthias And Abdillahi Suado M Novel polypeptides and medical uses thereof
AU2017252233A1 (en) 2016-04-22 2018-11-15 Alligator Bioscience Ab Novel bispecific polypeptides against CD137
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CN109310664A (zh) 2016-06-10 2019-02-05 田纳西大学研究基金会 选择性雄激素受体降解剂(sard)配体和其使用方法
US11230523B2 (en) 2016-06-10 2022-01-25 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10806719B2 (en) 2016-06-10 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
GB201611530D0 (en) 2016-07-01 2016-08-17 Alligator Bioscience Ab Novel polypeptides
WO2018064135A1 (en) 2016-09-30 2018-04-05 Asana Biosciences, Llc P2x3 and/or p2x2/3 compounds and methods
GB201619648D0 (en) 2016-11-21 2017-01-04 Alligator Bioscience Ab Novel antibodies and uses thereof
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
GB201701315D0 (en) 2017-01-26 2017-03-15 Enzymatica Ab Novel treatments
CA3070272A1 (en) 2017-07-20 2019-01-24 Aptevo Research And Development Llc Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
GB201800274D0 (en) 2018-01-08 2018-02-21 Enzymatica Ab Novel treatments
GB201801982D0 (en) 2018-02-07 2018-03-28 Enzymatica Ab Novel treatments
WO2019222556A1 (en) 2018-05-16 2019-11-21 Gtx, Inc. Selective androgen receptor degrader (sard) ligands and methods of use thereof
FR3082842A1 (fr) 2018-06-21 2019-12-27 Veru Inc. Polymorphe de cis-clomiphene (zuclomiphene) et procedes d'utilisation de celui-ci
US11253495B2 (en) 2018-11-21 2022-02-22 Yanming Wang Pharmaceutical composition for treating excessive lactate production and acidemia
EP3898679A2 (de) 2018-12-17 2021-10-27 Alligator Bioscience AB Polypeptide
WO2020127376A2 (en) 2018-12-17 2020-06-25 Alligator Bioscience Ab Novel polypeptides
GB201909298D0 (en) 2019-06-28 2019-08-14 Colzyx Ab Novel compositions and uses thereof
EP4069374A1 (de) 2019-12-06 2022-10-12 Thoas Fioretos Neuartige wirkstoffe und verwendungen davon
KR102350655B1 (ko) 2020-10-13 2022-01-12 인센 주식회사 테스토스테론-특이적 어피바디 및 이의 용도
GB202016456D0 (en) 2020-10-16 2020-12-02 Colzyx Ab Novel bioactive peptide combinations and uses thereof
GB202018187D0 (en) 2020-11-19 2021-01-06 Univ Southampton Compositions
EP4267625A1 (de) 2020-12-23 2023-11-01 Cantargia AB Anti-il1rap-antikörper
GB2603166A (en) 2021-01-29 2022-08-03 Thelper As Therapeutic and Diagnostic Agents and Uses Thereof
GB202102709D0 (en) 2021-02-25 2021-04-14 Univ Southampton Compounds
GB202102823D0 (en) 2021-02-26 2021-04-14 Tochikunda Ltd Diagnostic method
CN117203333A (zh) 2021-03-09 2023-12-08 诺瓦莱欣股份公司 抗菌多肽
EP4355780A1 (de) 2021-06-18 2024-04-24 Alligator Bioscience AB Neuartige kombinationstherapien und verwendungen davon
CN113695370B (zh) * 2021-08-30 2022-06-07 河北科技大学 一种天然低共熔离子液体及其制备方法和应用
AU2022381977A1 (en) 2021-11-05 2024-05-23 Alligator Bioscience Ab Novel peptides
GB202201137D0 (en) 2022-01-28 2022-03-16 Thelper As Therapeutic and diagnostic agents and uses thereof
WO2023166170A1 (en) 2022-03-03 2023-09-07 Targinta Ab Integrin alpha10 antibody
WO2023247050A1 (en) 2022-06-23 2023-12-28 Alligator Bioscience Ab Combination therapies
GB202210957D0 (en) 2022-07-27 2022-09-07 Alligator Bioscience Ab Novel dosages
GB202210965D0 (en) 2022-07-27 2022-09-07 Alligator Bioscience Ab Novel dosages
GB202212184D0 (en) 2022-08-22 2022-10-05 Univ Southampton Compounds
GB202215115D0 (en) 2022-10-13 2022-11-30 Univ Nottingham VEGF antibodies

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2213737A1 (de) 1972-03-22 1973-09-27 Hoechst Ag Lh-releasing hormon mit protrahierter wirkung
NO139560C (no) 1972-04-29 1979-04-04 Takeda Chemical Industries Ltd Analogifremgangsmaate til fremstilling av terapeutisk virksomme nonapeptidamid-derivater
JPS528375B2 (de) 1973-07-02 1977-03-09
FR2238700B1 (de) 1973-07-24 1977-10-14 Takeda Chemical Industries Ltd
JPS5726506B2 (de) 1974-03-08 1982-06-04
AT347054B (de) 1973-09-29 1978-12-11 Takeda Chemical Industries Ltd Verfahren zur herstellung von neuen nonapeptidamid-derivaten
DE2438352A1 (de) 1974-08-09 1976-02-26 Hoechst Ag Peptidcyclopropylamide mit lh-rh/fshrh-wirkung
DE2438350C3 (de) 1974-08-09 1979-06-13 Hoechst Ag, 6000 Frankfurt Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
NZ181036A (en) 1975-06-12 1978-12-18 A Schally Luteinising hormone releasing hormone analogues and intermediates therefor
US4010125A (en) 1975-06-12 1977-03-01 Schally Andrew Victor [D-Trp6 ]-LH-RH and intermediates therefor
FR2329293A1 (fr) 1975-10-29 1977-05-27 Parke Davis & Co Nouveaux nonapeptides et procedes pour leur production
US4093574A (en) 1977-02-02 1978-06-06 Eli Lilly And Company Somatostatin analogs and intermediates thereto
US4087390A (en) 1977-02-02 1978-05-02 Eli Lilly And Company Somatostatin analogs and intermediates thereto
JPS5944308B2 (ja) 1976-03-23 1984-10-29 武田薬品工業株式会社 ペプタイド
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US4100117A (en) 1977-04-21 1978-07-11 Eli Lilly And Company Somatostatin analogs and intermediates thereto
US4124577A (en) 1977-06-13 1978-11-07 Warner-Lambert Nonapeptides and methods for their production
US4218439A (en) 1977-07-14 1980-08-19 The Salk Institute For Biological Studies Peptide which inhibits gonadal function
US4253998A (en) 1979-03-09 1981-03-03 American Home Products Corporation Peptides related to somatostatin
JPS54148722A (en) 1978-05-12 1979-11-21 Takeda Chem Ind Ltd Nonapeptide and its preparation
US4277394A (en) 1979-04-23 1981-07-07 Takeda Chemical Industries, Ltd Tetrapeptidehydrazide derivatives
US4234571A (en) 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
US4317815A (en) 1979-06-13 1982-03-02 Coy David Howard LH-RH Antagonists
US4253997A (en) 1979-12-17 1981-03-03 American Home Products Corporation Anti-ovulatory decapeptides
JPS5692846A (en) 1979-12-27 1981-07-27 Takeda Chem Ind Ltd Tetrapeptide derivative and its preparation
CS230614B1 (en) 1982-08-06 1984-08-13 Martin Cs Flegel Analogues of realising factor for luteining and folliculstimulated hormon
US4569967A (en) 1983-10-24 1986-02-11 The Salk Institute For Biological Studies Synthesis of N-substituted peptide amides
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
JPH0720859B2 (ja) 1985-02-07 1995-03-08 武田薬品工業株式会社 マイクロカプセルの製造法
DE3678308D1 (de) * 1985-02-07 1991-05-02 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
JPH01171634A (ja) * 1987-12-26 1989-07-06 Toagosei Chem Ind Co Ltd 水又は水を主体とする液体のカプセルの製造方法
US5110904A (en) 1989-08-07 1992-05-05 Abbott Laboratories Lhrh analogs
CA2032559C (en) 1989-12-28 2001-11-06 Kiyofumi Ishikawa Endothelin antagonistic cyclic pentapeptides
IT1240643B (it) 1990-05-11 1993-12-17 Mediolanum Farmaceutici Spa Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano
US5284828A (en) 1990-05-14 1994-02-08 Fujisawa Pharmaceutical Co. Ltd. Peptide compound and its preparation
NO302481B1 (no) 1990-10-16 1998-03-09 Takeda Chemical Industries Ltd Polymer for et preparat med forlenget frigjöring, samt preparat med forlenget frigjöring
YU48420B (sh) * 1991-03-25 1998-07-10 Hoechst Aktiengesellschaft Postupak za dobijanje biološki razgradljivih mikročestica sa dugotrajnim delovanjem
WO1993015722A1 (en) * 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
AU4198793A (en) * 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
ES2110573T3 (es) * 1992-08-07 1998-02-16 Takeda Chemical Industries Ltd Produccion de microcapsulas de farmacos solubles en agua.
JP3277342B2 (ja) * 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
CA2192782C (en) * 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres

Also Published As

Publication number Publication date
JP2008291041A (ja) 2008-12-04
ATE305772T1 (de) 2005-10-15
DE69635249D1 (de) 2005-11-10
CA2192782C (en) 2008-10-14
EP0779072B1 (de) 2002-06-26
EP1142567B1 (de) 2005-10-05
ES2249362T3 (es) 2006-04-01
US5851451A (en) 1998-12-22
DE69622006D1 (de) 2002-08-01
EP1142567A3 (de) 2002-04-24
JP4988660B2 (ja) 2012-08-01
DK1142567T3 (da) 2006-02-06
PT1142567E (pt) 2005-11-30
EP1142567A2 (de) 2001-10-10
ATE219662T1 (de) 2002-07-15
US6036976A (en) 2000-03-14
EP0779072A1 (de) 1997-06-18
CA2192782A1 (en) 1997-06-16
DE69635249T2 (de) 2006-07-13

Similar Documents

Publication Publication Date Title
DE69622006T2 (de) Herstellung von Microspheren
CA2277136A1 (en) Particles containing absorbed liquids and methods of making them
ES524518A0 (es) Un procedimiento para preparar un agente anti-inflamatorio
CA2113901A1 (en) Preparation of microparticles
WO1997041837A3 (en) Microparticles
EP0235603A3 (de) Verfahren zum Herstellen gleichförmiger Tröpfchen
DE69233087D1 (de) Verfahren zur Herstellung von Polymerarrays
CA2151012A1 (fr) Emulsion eau-dans-huile sans tensioactif
ATE204469T1 (de) Verfahren zur herstellung von morphologisch einheitlichen mikrokapseln sowie nach diesem verfahren hergestellte mikrokapseln
KR930021261A (ko) 지지된 촉매, 이의 제조방법 및 비닐 아세테이트를 제조하기 위한 이의 용도
NO962994D0 (no) Framgangsmåte for framstilling av hule mikrosfærer
CA2036089A1 (en) Prolonged release microcapsules
AU2386595A (en) Aqueous solvent encapsulation method, apparatus and microcapsules
CA2076732A1 (en) Modified polysaccharides having improved absorbent properties and process for the preparation thereof
WO1993015130A3 (en) Process for increasing stability of poly(esteramides)
CA2024228A1 (en) Process for the production of expanded particles of a polyolefin resin
WO1996020972A3 (en) A process for the removal of a ph-basic material from a polyether polyol
CA2276364A1 (en) Novel water-in-oil microencapsulation process and microcapsules produced thereby
MY118174A (en) Process for the preparation of microparticles
EP0248362A3 (en) Process for the production of an active protein from a biologically inactive form
ATE164585T1 (de) Kristallisationsverfahren zur herstellung von glycerophosphocholin
EP0906931A3 (de) Entfernung von Lösungsmitteln aus Tröpfchen einer suspendierten Polymerlösung
CA2063441A1 (en) Cellulose chromatography support
RU95121237A (ru) Способ изготовления предохранительных деталей для защиты внутренней конической резьбы
DK0804234T3 (da) Adjuvans til vacciner

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: TAKEDA PHARMACEUTICAL CO. LTD., OSAKA, JP